Who are arformoterol (RR formoterol)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Arformoterol Tartrate Inhalation Solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/arformoterol-rr-formoterol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

arformoterol (RR formoterol) — Competitive Intelligence Brief

arformoterol (RR formoterol) (arformoterol (RR formoterol)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta-2 adrenergic agonist (LABA). Area: Respiratory.

marketed Long-acting beta-2 adrenergic agonist (LABA) Beta-2 adrenergic receptor (ADRB2) Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

arformoterol (RR formoterol) (arformoterol (RR formoterol)) — Henry Ford Health System. Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
arformoterol (RR formoterol) TARGET	arformoterol (RR formoterol)	Henry Ford Health System	marketed	Long-acting beta-2 adrenergic agonist (LABA)	Beta-2 adrenergic receptor (ADRB2)
Arformoterol Tartrate Inhalation Solution	Arformoterol Tartrate Inhalation Solution	Sumitomo Pharma America, Inc.	marketed	Long-acting beta-2 adrenergic agonist (LABA)	Beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting beta-2 adrenergic agonist (LABA) class)

Henry Ford Health System · 1 drug in this class
Sumitomo Pharma America, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). arformoterol (RR formoterol) — Competitive Intelligence Brief. https://druglandscape.com/ci/arformoterol-rr-formoterol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab